BCRX vs. VXRT

In the year-to-date period, BCRX achieves a 36.17% return, which is significantly higher than VXRT's -23.71% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for BioCryst Pharmaceuticals, Inc. (BCRX) and Vaxart, Inc. (VXRT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current BCRX Sharpe Ratio is 1.05, which is higher than the VXRT Sharpe Ratio of -0.50. The chart below compares the historical Sharpe Ratios of BCRX and VXRT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither BCRX nor VXRT has paid dividends to shareholders.

The maximum BCRX drawdown since its inception was -97.74%, roughly equal to the maximum VXRT drawdown of -98.69%. Use the drawdown chart below to compare losses from any high point for BCRX and VXRT. For additional features, visit the drawdowns tool.

The current volatility for BioCryst Pharmaceuticals, Inc. (BCRX) is 24.22%, while Vaxart, Inc. (VXRT) has a volatility of 31.12%. This indicates that BCRX experiences smaller price fluctuations and is considered to be less risky than VXRT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between BioCryst Pharmaceuticals, Inc. and Vaxart, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.